Phar­varis soars on mid-stage da­ta for se­vere swelling con­di­tion, rais­es $300M

Phar­varis im­me­di­ate­ly an­nounced the pric­ing of a $300 mil­lion of­fer­ing on Wednes­day af­ter dis­clos­ing pos­i­tive mid-stage da­ta on its oral drug for a rare, in­her­it­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER